Montelukast Sodium Global Market 2024 To Reach $5.59 Billion By 2028 At Rate Of 9.7%

July 23, 2024 03:18 PM IST | By EIN Presswire
 Montelukast Sodium Global Market 2024 To Reach $5.59 Billion By 2028 At Rate Of 9.7%
Image source: EIN Presswire

LANDON, GREATER LANDON, UK, July 23, 2024 /EINPresswire.com/ -- The montelukast sodium market has experienced robust growth in recent years, expanding from $3.52 billion in 2023 to $3.86 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increasing respiratory disorders, an aging population, rising air pollution levels, growing awareness and education, and expansion in emerging markets.

Strong Future Growth Anticipated

The montelukast sodium market is projected to continue its strong growth, reaching $5.59 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to approval and launch, clinical studies, patent expiry, regulatory changes, and physician prescribing patterns.

Explore Comprehensive Insights Into The Global Montelukast Sodium Market With A Detailed Sample Report:
https://www.thebusinessresearchcompany.com/sample_request?id=16123&type=smp

Growth Driver Of The Montelukast Sodium Market

The increasing prevalence of asthma is expected to propel the growth of montelukast sodium market going forward. Asthma is a chronic respiratory disorder marked by inflammation and constriction of the airways, resulting in repeated bouts of wheezing, breathlessness, chest tightness, and coughing. The prevalence of asthma is increasing due to environmental pollution, allergen exposure, genetic predisposition, urbanization, changes in lifestyle, and respiratory infections. Montelukast sodium is used in asthma as a leukotriene receptor antagonist, helping to prevent and manage asthma symptoms by blocking the action of leukotrienes, which contribute to airway inflammation and constriction.

Make Your Report Purchase Here And Explore The Whole Industry's Data As Well:
https://www.thebusinessresearchcompany.com/report/montelukast-sodium-global-market-report

Major Players And Market Trends

Key players in the montelukast sodium market include Pfizer Inc., Merck & Co. Inc., Sanofi Aventis SA, Teva Pharmaceuticals USA Inc., Hetero Labs Ltd., Sun Pharma Industries Ltd., Aurobindo Pharma Limited, Cipla Inc.

Major companies operating in the montelukast sodium market are developing new drugs such as fexofenadine hydrochloride and getting them approved to expand their product portfolios and address the evolving needs of patients with allergic conditions. Fexofinadine hydrochloride is a second-generation antihistamine medication approved by the FDA for treating allergy symptoms and hay fever in adults and children.

Segments:

1) By Product: Crystal-like, Form-less Or Amorphous
2) By Dosage Form: Tablets, Oral Solutions
3) By Application: Bronchospasm, Allergic Coryza, Asthma, Urticaria, Other Applications

Geographical Insights: North America Leading The Market

North America was the largest region in the montelukast sodium market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the montelukast sodium market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Montelukast Sodium Market Definition

Montelukast sodium is a leukotriene receptor antagonist, meaning it works by blocking the action of leukotrienes that cause asthma symptoms and allergic reactions. It is used to manage and prevent symptoms of asthma and to relieve seasonal and perennial allergic rhinitis. Montelukast is typically administered orally in tablet form.

Montelukast Sodium Global Market Report 2024 from The Business Research Company covers the following information:

• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Montelukast Sodium Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on montelukast sodium market size, montelukast sodium market drivers and trends, montelukast sodium market major players, montelukast sodium competitors' revenues, montelukast sodium market positioning, and montelukast sodium market growth across geographies. The montelukast sodium market report helps you gain in-depth insights into opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Sodium Cocoyl Isethionate Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-cocoyl-isethionate-global-market-report

Sodium Reduction Ingredients Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-reduction-ingredients-global-market-report

Sodium Lauryl Ether Sulfate [SLES] Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/sodium-lauryl-ether-sulfate-sles-global-market-report

About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
Facebook
X
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.